Surgical Innovations, a Leeds-based maker of keyhole-surgery instruments, has spent two years in turnaround mode. Losses are narrowing and margins are recovering, but Revenue is still slipping and the board is reviewing its options. Is a genuine comeback underway, or just a slower decline?

Introduction

Surgical Innovations Group (LSE:SUN) designs and manufactures instruments used in minimally invasive, or keyhole, surgery — the ports, graspers and hybrid reusable-disposable tools that surgeons rely on for laparoscopic operations. It is a genuinely small company: a Market Value of under £5m, a share price hovering around half a penny, and annual sales of roughly £11.6m. After a bruising couple of years of Margin pressure and mounting losses, management has been executing a self-described turnaround.

The headline asks whether this could become a healthcare comeback story. The 2025 figures show clear directional improvement — narrower losses, better margins and more cash — set against still-falling revenue and a board reviewing strategic options. This article weighs whether the recovery is durable, or merely a managed decline.

The Company

Surgical Innovations was founded in Leeds and has manufactured surgical devices there for decades. Its core Franchise is minimally invasive surgery: the flagship YelloPort port-access system and the Resposable range, which blends reusable and single-use components to cut cost and waste — a sustainability angle the company leans on heavily when selling into cost- and carbon-conscious health systems such as the NHS.

The Business runs two broad channels. SI-branded products, sold under its own name, are the larger and higher-margin part; an OEM arm manufactures for other medical-device firms. It also sells third-party products through distribution deals — including a five-year UK agreement with Microline valued at around £9m and partnerships with Peters Surgical, Aspen, Cipher and Veol — broadening its catalogue without the cost of developing every device in-house. Newer own-brand launches include the LogiTube gastric calibration tube, aimed at the fast-growing obesity-surgery market.

Geographically, the UK is the anchor, with sales in Europe, the US and Asia-Pacific. The company competes against far larger global players in a fragmented instruments market, where its edge is niche design, reusability and responsiveness rather than scale. Crucially, it recently secured Medical Device Regulation (MDR) certification, the European clearance needed to keep selling and to launch new devices.

Why the Stock Is in Focus

The interest is a turnaround narrative. For the year to 31 December 2025 the company cut its pre-tax loss to about £0.9m from £2.1m, lifted gross margin to roughly 33.7% from 30.7%, and grew cash to about £0.8m from just £0.2m a year earlier. Management has framed the strategy as a 'focus on the basics' — cost discipline, material optimisation and operational efficiency.

Two further catalysts stand out. MDR certification clears the path for a wave of new products — LogiTube Lux, Logi Grasp and Logi Dissect — slated for the first half of 2026, and management pointed to positive first-quarter trading and a return to growth this year. Perhaps most significant for shareholders, the board has said it is reviewing the business's strategy to identify Options to maximise value — language that markets often read as opening the door to a sale, Merger or other corporate action.

Financial Position

The 2025 results show a company stabilising but not yet healthy. Revenue slipped about 2.5% to £11.6m from £11.9m, as SI-branded sales fell around 8% on US Tariff headwinds and difficulties in India, partly offset by 14% growth in UK distribution. The operating loss narrowed slightly to about £0.7m, and the net loss roughly halved to about £0.9m from £1.9m. However, adjusted EBITDA turned negative at about minus £0.4m, from a small positive the year before — a reminder the underlying business is not yet reliably cash-generative.

The Balance Sheet is modest. Cash of about £0.8m improved markedly, but net Debt was around £0.3m, leaving limited headroom. No Dividend is paid. With roughly 933 million shares in issue and a price near 0.5p, the Market Capitalisation is about £4.7m, and the stock has fallen around 29% over the past year within a 52-week range of roughly 0.33p to 0.74p. On those numbers the shares trade well below annual revenue — cheap to some, a fair reflection of thin margins and execution risk to others. These figures are drawn from the FY2025 results and market data.

Bull Case

The optimistic case is that the hard work is starting to show. Losses are shrinking, gross margin is recovering and cash has more than trebled — evidence the cost restructuring is landing. MDR certification removes a regulatory overhang and unlocks a 2026 product pipeline, while exposure to obesity surgery and NHS sustainability procurement offers structural tailwinds. The distribution deals add revenue at low incremental cost. And with the board reviewing options, a trade buyer could see value in an established, MDR-certified UK manufacturer at a sub-£5m valuation. If revenue returns to growth as guided, the operational Leverage could be meaningful.

Bear Case and Risks

The risks are real. Revenue has now declined for two consecutive years, and negative adjusted EBITDA shows the core operation is still not covering its costs. The company is small, thinly financed with modest net debt, and exposed to tariff and supply-chain shocks that hit the 2025 numbers. Reliance on the NHS ties it to a stretched public buyer, and competition from far larger device makers is relentless. A strategic review may deliver nothing, or a deal at a low price. As an AIM micro-cap the shares are Illiquid and volatile, and any fresh setback could force dilutive fundraising. A comeback requires sustained growth the company has not yet shown.

What Investors Should Watch Next

The most important signal is the top line: does 2026 deliver the guided return to revenue growth, and does adjusted EBITDA move back into positive territory? Watch the H1 2026 launches of LogiTube Lux, Logi Grasp and Logi Dissect and their early sales traction. Track the strategic review for any concrete outcome — a partnership, disposal or offer. Keep an eye on cash and net debt, US tariff developments, and whether UK distribution momentum offsets branded weakness.

Conclusion

Could Surgical Innovations become a healthcare comeback story? The 2025 results make the case more credible than it was: losses have roughly halved, margins have recovered and cash has improved, all while the company cleared the MDR hurdle. But a comeback is not yet proven. Revenue is still falling, the core business remains loss-making at the EBITDA line, and the balance sheet leaves little room for error. The next twelve months — the product launches, the promised return to growth and the strategic review — will decide whether this is a genuine turnaround or a slower decline. Investors should watch the revenue line above all.